Cargando…

Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study

PURPOSE: This study aims to investigate the effect of sorafenib plus Transarterial Chemoembolization (TACE) treatment on inhibiting portal vein invasion in patients with intermediate stage HCC. MATERIALS AND METHODS: The consecutive medical records of patients with HCC were retrospectively analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Qi, Zhang, Hongsen, Xiong, Bin, Zheng, Chuansheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668016/ https://www.ncbi.nlm.nih.gov/pubmed/29108283 http://dx.doi.org/10.18632/oncotarget.20745

Ejemplares similares

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
por: Zhang, Leida, et al.
Publicado: (2014)

A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus
por: Zhang, Zeyu, et al.
Publicado: (2022)

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
por: Luz, Jose Hugo Mendes, et al.
Publicado: (2017)

Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
por: Zhang, XiuPing, et al.
Publicado: (2017)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Prospective study of TACE combined with sorafenib vs TACE combined with (125)I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas
por: Zhao, Xiao-Hui, et al.
Publicado: (2022)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Irradiation stent with (125)I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial
por: Lu, Jian, et al.
Publicado: (2023)

Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
por: Zheng, Liyun, et al.
Publicado: (2021)

Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study
por: Chen, Ligang, et al.
Publicado: (2018)

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
por: Qu, Xu-Dong, et al.
Publicado: (2012)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis
por: Lu, Haohao, et al.
Publicado: (2021)

Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study
por: Xiang, Hua, et al.
Publicado: (2019)

Macroscopic Portal Vein Thrombosis in HCC Patients
por: Akkiz, Hikmet, et al.
Publicado: (2018)

Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study
por: Cao, Yanyan, et al.
Publicado: (2021)

Efficacy and Safety of TACE Combined with Regorafenib versus TACE in the Third-Line Treatment of Colorectal Liver Metastases
por: Lu, Haohao, et al.
Publicado: (2022)

Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study
por: Lu, Haohao, et al.
Publicado: (2023)

Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus
por: Yang, Biao, et al.
Publicado: (2018)

Portal Vein Damage after DEB-TACE and Lipiodol-TACE: Based on Evaluation by Computed Tomography during Arterial Portography
por: Tamura, Masashi, et al.
Publicado: (2021)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study
por: Yuan, Jia, et al.
Publicado: (2019)

Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Liu, Shanshan, et al.
Publicado: (2023)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
por: Wu, Jianbing, et al.
Publicado: (2017)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
por: Zhu, Yejing, et al.
Publicado: (2023)

Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis
por: Lu, Haohao, et al.
Publicado: (2021)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
por: Qiu, Zhiyu, et al.
Publicado: (2021)

Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?
por: Somma, Francesco, et al.
Publicado: (2015)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Chemotherapy combined with radiotherapy can benefit more unresectable HCC patients with portal and/or hepatic vein invasion: a retrospective analysis of the SEER database
por: Qiu, Xiaotong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ef72pef1b0el8vs7tcreu25nsa